Cargando…

Overexpression of Class III Beta Tubulin and Amplified HER2 Gene Predict Good Response to Paclitaxel and Trastuzumab Therapy

Through this study, we aimed to validate several biomarkers that have been known to possibly predict the outcomes of the trastuzumab and paclitaxel (TP). Human epidermal growth factor 2 (HER2) positive metastatic breast cancer (MBC) patients who had been treated with TP in single institute from 2006...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jung, Minkyu, Koo, Ja Seung, Moon, Young Wha, Park, Byeong-Woo, Kim, Seung Il, Park, Seho, Lee, Soo Hyun, Hong, Soojung, Rha, Sun Young, Chung, Hyun Cheol, Kim, Joo Hang, Sohn, Joohyuk
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3447874/ https://www.ncbi.nlm.nih.gov/pubmed/23028798 http://dx.doi.org/10.1371/journal.pone.0045127

Ejemplares similares

Cardiotoxicity of trastuzumab in patients with HER2-positive gastric cancer
por: Soo Park, Ji, et al.
Publicado: (2017)

Real-World Clinical Outcomes of Biosimilar Trastuzumab (CT-P6) in HER2-Positive Early-Stage and Metastatic Breast Cancer
por: Bae, Soong June, et al.
Publicado: (2021)

S-1 combined with docetaxel following doxorubicin plus cyclophosphamide as neoadjuvant therapy in breast cancer: phase II trial
por: Moon, Yong Wha, et al.
Publicado: (2013)

Feasibility of Charcoal Tattooing of Cytology-Proven Metastatic Axillary Lymph Node at Diagnosis and Sentinel Lymph Node Biopsy after Neoadjuvant Chemotherapy in Breast Cancer Patients
por: Park, Seho, et al.
Publicado: (2018)

PTEN loss and level of HER2 amplification is associated with trastuzumab resistance and prognosis in HER2-positive gastric cancer
por: Kim, Chan, et al.
Publicado: (2017)

Magnetic Resonance Imaging after Completion of Neoadjuvant Chemotherapy Can Accurately Discriminate between No Residual Carcinoma and Residual Ductal Carcinoma In Situ in Patients with Triple-Negative Breast Cancer
por: Park, Seho, et al.
Publicado: (2016)

Depth of response is a significant predictor for long-term outcome in advanced gastric cancer patients treated with trastuzumab
por: Lee, Choong-Kun, et al.
Publicado: (2017)

A single arm phase Ib/II trial of first-line pembrolizumab, trastuzumab and chemotherapy for advanced HER2-positive gastric cancer
por: Lee, Choong-kun, et al.
Publicado: (2022)

Anaplastic Lymphoma Kinase Gene Copy Number Gain in Inflammatory Breast Cancer (IBC): Prevalence, Clinicopathologic Features and Prognostic Implication
por: Kim, Min Hwan, et al.
Publicado: (2015)

Weekly Paclitaxel and Trastuzumab as a First-Line Therapy in Patients with HER2-Overexpressing Metastatic Breast Cancer: Magnitude of HER2/neu Amplification as a Predictive Factor for Efficacy
por: Han, Hye-Suk, et al.
Publicado: (2009)

CD44/CD24 and aldehyde dehydrogenase 1 in estrogen receptor-positive early breast cancer treated with tamoxifen: CD24 positivity is a poor prognosticator
por: Moon, Yong Wha, et al.
Publicado: (2017)

Phase II study of DHP107 (oral paclitaxel) in the first-line treatment of HER2-negative recurrent or metastatic breast cancer (OPTIMAL study)
por: Kim, Sung-Bae, et al.
Publicado: (2021)

Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer
por: Canonici, Alexandra, et al.
Publicado: (2013)

Paclitaxel-Trastuzumab Mixed Nanovehicle to Target HER2-Overexpressing Tumors
por: Nieto, Celia, et al.
Publicado: (2019)

A Phase II Study to Evaluate the Safety and Efficacy of Pegteograstim in Korean Breast Cancer Patients Receiving Dose-Dense Doxorubicin/Cyclophosphamide
por: Kim, Gun Min, et al.
Publicado: (2019)

Monitoring the Outcomes of Systemic Chemotherapy Including Immune Checkpoint Inhibitor for HER2-Positive Metastatic Gastric Cancer by Liquid Biopsy
por: Jung, Seung-Hyun, et al.
Publicado: (2023)

Efficacy and Safety of Trastuzumab Biosimilar (CT-P6) Compared With Reference Trastuzumab in Patients With HER2-positive Advanced Gastric Cancer: A Retrospective Analysis
por: Park, Joo-Hwan, et al.
Publicado: (2022)

Tumor Heterogeneity in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer Assessed by CT Texture Analysis: Association with Survival after Trastuzumab Treatment
por: Yoon, Sung Hyun, et al.
Publicado: (2016)

Detection of Circulating Tumor Cells in Breast Cancer Patients Using Cytokeratin-19 Real-Time RT-PCR
por: Park, Hyung Seok, et al.
Publicado: (2017)

A Retrospective Analysis for Patients with HER2-Positive Gastric Cancer Who Were Treated with Trastuzumab-Based Chemotherapy: In the Perspectives of Ethnicity and Histology
por: Yi, Jun Ho, et al.
Publicado: (2016)

Mechanisms Behind the Resistance to Trastuzumab in HER2-Amplified Breast Cancer and Strategies to Overcome It
por: Luque-Cabal, María, et al.
Publicado: (2016)

Lack of both androgen receptor and forkhead box A1 (FOXA1) expression is a poor prognostic factor in estrogen receptor-positive breast cancers
por: Park, Seho, et al.
Publicado: (2017)

Pathological complete response to neoadjuvant trastuzumab and pertuzumab therapy is related to human epidermal growth factor receptor 2 (HER2) amplification level in HER2-amplified breast cancer
por: Choi, Jin Hyuk, et al.
Publicado: (2020)

Is the frozen section examination for sentinel lymph node necessary in early breast cancer patients?
por: Yoon, Kwang Hyun, et al.
Publicado: (2019)

Axillary response according to neoadjuvant single or dual human epidermal growth factor receptor 2 (HER2) blockade in clinically node‐positive, HER2‐positive breast cancer
por: Cha, Chihwan, et al.
Publicado: (2021)

Randomised Phase 2 study of lapatinib and vinorelbine vs vinorelbine in patients with HER2 + metastatic breast cancer after lapatinib and trastuzumab treatment (KCSG BR11-16)
por: Sim, Sung Hoon, et al.
Publicado: (2019)

Therapeutic Response Monitoring with (89)Zr-DFO-Pertuzumab in HER2-Positive and Trastuzumab-Resistant Breast Cancer Models
por: Kang, Minwoo, et al.
Publicado: (2022)

Synthesis and Feasibility Evaluation of a new Trastuzumab Conjugate Integrated with Paclitaxel and (89)Zr for Theranostic Application Against HER2‐Expressing Breast Cancers
por: Jang, Joo Hee, et al.
Publicado: (2019)

Trastuzumab and paclitaxel in patients with EGFR mutated NSCLC that express HER2 after progression on EGFR TKI treatment
por: de Langen, Adrianus J., et al.
Publicado: (2018)

How Many Sentinel Lymph Nodes Are Enough for Accurate Axillary Staging in T1-2 Breast Cancer?
por: Ban, Eun Jeong, et al.
Publicado: (2011)

The Impact of Concomitant Genomic Alterations on Treatment Outcome for Trastuzumab Therapy in HER2-Positive Gastric Cancer
por: Lee, Ji Yun, et al.
Publicado: (2015)

PF-05280014 (a trastuzumab biosimilar) plus paclitaxel compared with reference trastuzumab plus paclitaxel for HER2-positive metastatic breast cancer: a randomised, double-blind study
por: Pegram, Mark D., et al.
Publicado: (2018)

Trastuzumab and pertuzumab in circulating tumor DNA ERBB2-amplified HER2-positive refractory cholangiocarcinoma
por: Yarlagadda, Bhavya, et al.
Publicado: (2019)

A novel HSP90 inhibitor targeting the C-terminal domain attenuates trastuzumab resistance in HER2-positive breast cancer
por: Park, Jung Min, et al.
Publicado: (2020)

On-treatment derived neutrophil-to-lymphocyte ratio and survival with palbociclib and endocrine treatment: analysis of a multicenter retrospective cohort and the PALOMA-2/3 study with immune correlates
por: Kim, Chang Gon, et al.
Publicado: (2023)

Next-generation sequencing of BRCA1/2 in breast cancer patients: potential effects on clinical decision-making using rapid, high-accuracy genetic results
por: Park, Hyung Seok, et al.
Publicado: (2017)

A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study)
por: Patel, Tejal A., et al.
Publicado: (2019)

Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer
por: Yu, Anthony F., et al.
Publicado: (2016)

Phase II study to investigate the efficacy of trastuzumab biosimilar (Herzuma®) plus treatment of physician's choice (TPC) in patients with heavily pretreated HER-2+ metastatic breast cancer (KCSG BR 18–14/KM10B)
por: Sim, Sung Hoon, et al.
Publicado: (2022)

Genetic and immune microenvironment characterization of HER2‐positive gastric cancer: Their association with response to trastuzumab‐based treatment
por: Kwon, Hyun Jung, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_e6u4husn8d642n31uc2ir32t8l